Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shandong Keyuan Pharmaceutical Co has the GF Score of 67, which implies that the company
might have
Poor future performance potential.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Based on research and backtesting result, GuruFocus believes Shandong Keyuan Pharmaceutical Co
might have
Poor future performance potential.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
Shandong Keyuan Pharmaceutical Co (SZSE:301281) GF Score Explanation
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score
Performance Potential and All-in-One Screener Examples (1)
(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.
Shandong Keyuan Pharmaceutical Co GF Score Related Terms
SZSE:301281 vs LLY, JNJ, ABBV: GF Score Comparison
For the Drug Manufacturers - General subindustry, Shandong Keyuan Pharmaceutical Co's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shandong Keyuan Pharmaceutical Co GF Score vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Shandong Keyuan Pharmaceutical Co's GF Score distribution charts can be found below:
* The bar in red indicates where Shandong Keyuan Pharmaceutical Co's GF Score falls into.
Shandong Keyuan Pharmaceutical Co (SZSE:301281) has a GF Score of 67 as of Jul. 15, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Shandong Keyuan Pharmaceutical Co and its competitors. This is 103% above median its historical median of 33.00. Over the past decade, Shandong Keyuan Pharmaceutical Co's GF Score has ranged from 19.00 to 78.00.
Is Shandong Keyuan Pharmaceutical Co's GF Score too high?
Shandong Keyuan Pharmaceutical Co's current GF Score of 67 is 103% above median its 10-year median of 33.00. Over the past 10 years, this metric has ranged from a low of 19.00 to a high of 78.00. Overall, Shandong Keyuan Pharmaceutical Co has a GF Score™ of 67/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shandong Keyuan Pharmaceutical Co's GF Score compare to LLY and JNJ?
Shandong Keyuan Pharmaceutical Co's GF Score of 67 can be compared against companies in the Drug Manufacturers industry. Historically, Shandong Keyuan Pharmaceutical Co's own GF Score has ranged from 19.00 to 78.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Drug Manufacturers company?
A good GF Score depends on the Drug Manufacturers industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Shandong Keyuan Pharmaceutical Co and its competitors. Shandong Keyuan Pharmaceutical Co's current GF Score is 67, which is 103% above median its own 10-year median of 33.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shandong Keyuan Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Shandong Keyuan Pharmaceutical Co (SZSE:301281) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥30.44, compared to a current price of ¥50.60 — trading 66.2% above its estimated fair value. The current GF Score is 67, which is 103% above median its 10-year median of 33.00. Shandong Keyuan Pharmaceutical Co's overall GF Score™ is 67/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Shandong Keyuan Pharmaceutical Co (SZSE:301281), the current GF Score is 67 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shandong Keyuan Pharmaceutical Co (SZSE:301281) Overvalued in 2026?
Based on GuruFocus' analysis, Shandong Keyuan Pharmaceutical Co stock appears to be overvalued.
The current stock price of ¥50.60 is trading 66.2% above its estimated GF Value™ of ¥30.44.
GuruFocus considers Shandong Keyuan Pharmaceutical Co to be Significantly Overvalued.
Key valuation signals for SZSE:301281:
GF Score: 67 (103% above median its 10-year median of 33.00)
GF Value™: ¥30.44 vs. price of ¥50.60 (66.2% above fair value)
No single metric tells the full story. See the SZSE:301281 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shandong Keyuan Pharmaceutical Co Business Description
Shandong Keyuan Pharmaceutical Co Ltd is engaged in the research and development, production, and sales of chemical raw materials and their preparations.
67GF Score
Get the complete analysis for SZSE:301281
GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SZSE:301281 has been successfully added to your 
